{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:45:52Z","timestamp":1791434752502,"version":"4.3.3"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.bioorg.2025.108231","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T16:38:27Z","timestamp":1738255107000},"page":"108231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["New indolin-2-ones, possessing sunitinib scaffold as HDAC inhibitors and anti-cancer agents with potential VEGFR inhibition activity; design, synthesis and biological evaluation"],"prefix":"10.1016","volume":"156","author":[{"given":"Mozhdeh","family":"Yousefian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Eskandarpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Zarghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzin","family":"Hadizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razieh","family":"Ghodsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108231_b0005","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41420-024-01803-z","article-title":"Cancer epigenetics: from laboratory studies and clinical trials to precision medicine","volume":"10","author":"Yu","year":"2024","journal-title":"Cell. Death. Discov."},{"key":"10.1016\/j.bioorg.2025.108231_b0010","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.3390\/cancers16101794","article-title":"Angiogenesis Still Plays a Crucial Role in Human Melanoma Progression","volume":"16","author":"Cazzato","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2025.108231_b0015","article-title":"VEGF signaling: Role in angiogenesis and beyond, Biochimica et Biophysica Acta (BBA) Reviews on","volume":"1879","author":"Shaw","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2025.108231_b0020","doi-asserted-by":"crossref","first-page":"25682","DOI":"10.1038\/s41598-024-76258-4","article-title":"Targeting the VEGFR2 signaling pathway for angiogenesis and fibrosis regulation in neovascular age-related macular degeneration","volume":"14","author":"Yu","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.108231_b0025","article-title":"Recent advances of anti-angiogenic inhibitors targeting VEGF\/VEGFR axis","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108231_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.136448","article-title":"Novel azole-urea hybrids as VEGFR-2 inhibitors: Synthesis, in vitro antiproliferative evaluation and in silico studies","volume":"1294","author":"Shirzad","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2025.108231_b0035","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.3390\/life11101070","article-title":"Identification of Novel Potential VEGFR-2 Inhibitors Using a Combination of Computational Methods for Drug Discovery","volume":"11","author":"Alsanea","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.bioorg.2025.108231_b0040","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3390\/cancers16020350","article-title":"Exploring the Spectrum of VEGF Inhibitors' Toxicities from Systemic to Intra-Vitreal Usage in Medical Practice","volume":"16","author":"Santorsola","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2025.108231_b0045","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13045-022-01310-7","article-title":"Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy","volume":"15","author":"Liu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2025.108231_b0050","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/genes11050556","article-title":"Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability","volume":"11","author":"Milazzo","year":"2020","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.bioorg.2025.108231_b0055","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: the histone deacetylase enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold. Spring. Harb. Perspect. Biol"},{"key":"10.1016\/j.bioorg.2025.108231_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.141011","article-title":"Design, synthesis, biological evaluation and molecular docking study of novel quinolone derivatives as potent HDAC1 (Histone Deacetylase) inhibitors and anticancer agents","volume":"1325","author":"Eskandarpour","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2025.108231_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120946","article-title":"Current trends in development of HDAC-based chemotherapeutics","volume":"308","author":"Cheshmazar","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.bioorg.2025.108231_b0070","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC Inhibitors in Cancer Development and Therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold. Spring. Harb. Perspect. Med."},{"key":"10.1016\/j.bioorg.2025.108231_b0075","doi-asserted-by":"crossref","DOI":"10.3390\/ph17050620","article-title":"The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods","volume":"17","author":"Curcio","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bioorg.2025.108231_b0080","first-page":"1049","article-title":"The clinical development of histone deacetylase inhibitors as targeted anticancer drugs, Expert. Opin. Investig","volume":"19","author":"Marks","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2025.108231_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/1120009X.2024.2411825","article-title":"Developing new drugs for adult T-cell leukemia\/lymphoma by targeting hypoxia: insights from toxicity of MS-275 and its analogs","author":"Goudarzi","year":"2024","journal-title":"J. Chemothe."},{"key":"10.1016\/j.bioorg.2025.108231_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.136951","article-title":"Design, synthesis and biological evaluation of novel imidazole-based benzamide and hydroxamic acid derivatives as potent histone deacetylase inhibitors and anticancer agents","volume":"1297","author":"Nasrollahzadeh","year":"2024","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2025.108231_b0095","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1007\/s00044-021-02776-9","article-title":"Dual HDAC\/BRD4 inhibitors against cancer","volume":"30","author":"Omidkhah","year":"2021","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2025.108231_b0100","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s00044-023-03018-w","article-title":"Synthesis, cytotoxicity, Pan-HDAC inhibitory activity and docking study of new N-(2-aminophenyl)-2-methylquinoline-4-carboxamide and (E)-N-(2-aminophenyl)-2-styrylquinoline-4-carboxamide derivatives as anticancer agents","volume":"32","author":"Omidkhah","year":"2023","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2025.108231_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.137749","article-title":"Design, synthesis, biological evaluation and molecular docking study of novel chalcone-based hydroxamic acids possessing a central 2, 4-dimethy pyrrole linker as potential HDAC (Histone Deacetylase) inhibitors and anticancer agents","volume":"1305","author":"Yousefian","year":"2024","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2025.108231_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107278","article-title":"Recent development of VEGFR small molecule inhibitors as anticancer agents: A patent review (2021\u20132023)","volume":"146","author":"Zeng","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108231_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106425","article-title":"Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy","volume":"133","author":"Liu","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108231_b0120","doi-asserted-by":"crossref","first-page":"24460","DOI":"10.1038\/srep24460","article-title":"Discovery of potent VEGFR-2 inhibitors based on furopyrimidine and thienopyrimidne scaffolds as cancer targeting agents","volume":"6","author":"Aziz","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.108231_b0125","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s43094-024-00688-0","article-title":"Exploring the potential of small molecules of dual c-Met and VEGFR inhibitors for advances and future drug discovery in cancer therapy","volume":"10","author":"Dhawale","year":"2024","journal-title":"Future. J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2025.108231_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105105","article-title":"Discovery of new quinoxaline-2 (1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation","volume":"114","author":"El-Adl","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108231_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2019.100009","article-title":"Vascular endothelial growth factor receptor (VEGFR-2)\/KDR inhibitors: medicinal chemistry perspective","volume":"2","author":"Modi","year":"2019","journal-title":"Med. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.108231_b0140","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/13543776.2017.1344215","article-title":"VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016)","volume":"27","author":"Peng","year":"2017","journal-title":"Expert. Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2025.108231_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107243","article-title":"Benzimidazole-oxindole hybrids as multi-kinase inhibitors targeting melanoma","volume":"146","author":"Allam","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108231_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104532","article-title":"Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma","volume":"107","author":"Eissa","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108231_b0155","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202000022","article-title":"Structure-activity relationship studies of indolin-2-one derivatives as vascular endothelial growth factor receptor inhibitors and anticancer agents","volume":"353","author":"Yousefian","year":"2020","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2025.108231_b0160","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejmech.2014.05.051","article-title":"Synthesis and invivo SAR study of indolin-2-one-based multi-targeted inhibitors as potential anticancer agents","volume":"82","author":"Zhang","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108231_b0165","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejmech.2015.05.040","article-title":"Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, invitro biological evaluation and molecular docking","volume":"100","author":"Eldehna","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108231_b0170","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1016\/j.bmc.2015.05.048","article-title":"Design, synthesis and preliminary biological evaluation of indoline-2, 3-dione derivatives as novel HDAC inhibitors","volume":"23","author":"Jin","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108231_b0175","article-title":"Discovery of spirooxindole-derived small-molecule compounds as novel HDAC\/MDM2 dual inhibitors and investigation of their anticancer activity","volume":"2","author":"Zhao","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2025.108231_b0180","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","article-title":"Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas","volume":"120","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res"},{"key":"10.1016\/j.bioorg.2025.108231_b0185","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1124\/dmd.111.042853","article-title":"Pharmacokinetics, Distribution, and Metabolism of Sunitinib in Rats, Monkeys, and Humans","volume":"40","author":"Speed","year":"2012","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.bioorg.2025.108231_b0190","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1080\/00397919408010603","article-title":"A New Efficient and Mild Synthesis of 2-Sxindoles by One-Pot Wolff-Kishner Like Reduction of Isatin Derivatives","volume":"24","author":"Crestini","year":"1994","journal-title":"Synth. Commun."},{"key":"10.1016\/j.bioorg.2025.108231_b0195","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2174\/2213337206666190306155140","article-title":"Recent synthetic methodologies for chalcone synthesis","volume":"6","author":"Farooq","year":"2019","journal-title":"Curr. Organocatal."},{"key":"10.1016\/j.bioorg.2025.108231_b0200","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/00397910903026723","article-title":"Synthesis of hydroxamic acids by activation of carboxylic acids with N, N\u2032-carbonyldiimidazole: exploring the efficiency of the method","volume":"40","author":"Usachova","year":"2010","journal-title":"Synth. Commun."},{"key":"10.1016\/j.bioorg.2025.108231_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.140334","article-title":"Synthesis, cytotoxicity, docking, MD simulation, drug-likeness, ADMET prediction and multi spectroscopic studies of some novel quinoline-4-carboxamide derivatives as DNA intercalating and anticancer agents","volume":"1322","author":"Omidkhah","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2025.108231_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.108098","article-title":"Design, synthesis, biological evaluation and multi spectroscopic studies of novel 2-styrylquinoline-carboxamide derivatives as potential DNA intercalating anticancer agents","volume":"154","author":"Omidkhah","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108231_b0215","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1186\/s12885-017-3578-9","article-title":"VEGFR2 regulates endothelial differentiation of colon cancer cells","volume":"17","author":"Liu","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2025.108231_b0220","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201800307","article-title":"Synthesis and biological evaluation of novel benzo [c] acridine\u2010diones as potential anticancer agents and tubulin polymerization inhibitors","volume":"352","author":"Behbahani","year":"2019","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2025.108231_b0225","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1016\/j.bmc.2017.03.066","article-title":"The synthesis and evaluation of new butadiene derivatives as tubulin polymerization inhibitors","volume":"25","author":"Pang","year":"2017","journal-title":"Bioorg.med. Chem."},{"key":"10.1016\/j.bioorg.2025.108231_b0230","article-title":"Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF\/VEGFR-2 signaling pathway","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2025.108231_b0235","first-page":"1282","article-title":"Abdelshafy Abdelhamid, Chalcones incorporated pyrazole ring inhibit proliferation, cell cycle progression, angiogenesis and induce apoptosis of MCF7 cell line, Anti-Cancer Agents","volume":"14","author":"Mohamed","year":"2014","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108231_b0240","doi-asserted-by":"crossref","first-page":"18281","DOI":"10.1073\/pnas.1207759109","article-title":"Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors","volume":"109","author":"McTigue","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2025.108231_b0245","doi-asserted-by":"crossref","first-page":"28462","DOI":"10.1039\/D3RA05542F","article-title":"Design, synthesis and biological evaluation of VEGFR-2\/HDAC dual inhibitors as multitargeted antitumor agents based on fruquintinib and vorinostat","volume":"13","author":"Gao","year":"2023","journal-title":"RSC .adv."},{"key":"10.1016\/j.bioorg.2025.108231_b0250","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.drudis.2019.10.014","article-title":"A drug-likeness toolbox facilitates ADMET study in drug discovery","volume":"25","author":"Jia","year":"2020","journal-title":"Drug. Discov. Today."},{"key":"10.1016\/j.bioorg.2025.108231_b0255","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta. Pharm. Sin b."},{"key":"10.1016\/j.bioorg.2025.108231_b0260","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd3367","article-title":"Probing the links between in vitro potency, ADMET and physicochemical parameters","volume":"10","author":"Gleeson","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.108231_b0265","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108231_b0270","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.108231_b0275","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/cmdc.201600182","article-title":"A boiled\u2010egg to predict gastrointestinal absorption and brain penetration of small molecules","volume":"11","author":"Daina","year":"2016","journal-title":"Chem. Med. Chem"},{"key":"10.1016\/j.bioorg.2025.108231_b0280","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10456-008-9117-1","article-title":"The chick embryo chorioallantoic membrane as a model to study tumor metastasis","volume":"11","author":"Cimpean","year":"2008","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bioorg.2025.108231_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104553","article-title":"Quinazolin-4 (3H)-one based agents bearing thiadiazole-urea: Synthesis and evaluation of anti-proliferative and antiangiogenic activity","volume":"108","author":"Faraji","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108231_b0290","doi-asserted-by":"crossref","first-page":"14718","DOI":"10.18632\/aging.103531","article-title":"Demethoxycurcumin analogue DMC-BH inhibits orthotopic growth of glioma stem cells by targeting JNK\/ERK signaling","volume":"12","author":"Shi","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.bioorg.2025.108231_b0295","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1021\/jm301254q","article-title":"Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells","volume":"56","author":"Marek","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108231_b0300","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejmech.2017.03.024","article-title":"Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents","volume":"132","author":"Abdizadeh","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108231_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.133599","article-title":"Synthesis, structure activity relationship and biological evaluation of a novel series of quinoline\u2013based benzamide derivatives as anticancer agents and histone deacetylase (HDAC) inhibitors","volume":"1267","author":"Omidkhah","year":"2022","journal-title":"J. Mol. Struct."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825001117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825001117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T02:08:10Z","timestamp":1758852490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825001117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":61,"alternative-id":["S0045206825001117"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108231","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New indolin-2-ones, possessing sunitinib scaffold as HDAC inhibitors and anti-cancer agents with potential VEGFR inhibition activity; design, synthesis and biological evaluation","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108231","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108231"}}